Neurotech Transforms the Delivery of Biologics

Ted Danse, President & CEO for Neurotech, begins by touching upon their ETC technology platform, labeling it as “transformational” in its ability to deliver biologics over multiple years with one simple and minimally invasive procedure. Continuing to detail the key components of their program, Ted expands on the company’s progress thus far. Presenter: Edward (Ted)…

Read More

ALG1001 Leads Allegro’s Progress in Retinal Diseases

Vicken Karageozian, Co-Founder & CTO for Allegro Ophthalmics, shares his company’s story and highlights the progress of their lead molecule, ALG1001, a lead program for several retinal diseases. This program offers a long duration of effect, the option of using combination therapy and treatment for patients who have plateaued or are no longer responding to…

Read More